Nephrology

A longitudinal cohort study shows a lack of correlation between decreased proteinuria levels and improved treatment, renal responses in patients.

Decreased serum albumin levels can be a tool for predicting the risk of cancer and mortality in patients undergoing hemodialysis.

Findings suggest people with reduced kidney function have higher levels of Alzheimer’s biomarkers in their blood but not an increased risk of dementia.

A single-center retrospective survey urges clinicians to address recurrent urinary tract infections in kidney transplant recipients.

Findings from a meta-analysis show peritoneal dialysis might preserve cognitive function compared to hemodialysis in chronic kidney disease.

In a cross-sectional OCTA analysis of patients with referable diabetic retinopathy, CKD emerges as an independent predictor of higher MA burden.

A multicenter study outlines stage-specific risk factors, protective traits for sarcopenia in older adults on maintenance hemodialysis, supporting earlier screening.

Key FDA approvals, pivotal IgAN and glomerular trial results, and transplant and CKD insights from November 2025.

A competing mortality-risk model improves calibration and captures more true 5-year kidney failure events.

The acceptance comes on the heels of positive topline results comparing the new device to the current on-body infusor.

Meta-analysis shows semaglutide lowers cardiovascular and kidney risks while supporting safety in adults with chronic kidney disease.

FDA grants accelerated approval for sibeprenlimab for reducing proteinuria in IgA nephropathy.

International registry analysis highlights consistent outcomes, calls for global collaboration in managing high-risk post-transplant pregnancies.

Patients with MASLD, advanced CKM stages face higher mortality and liver fibrosis, emphasizing the need for early risk assessment.

Pediatric IgA nephropathy shows slow progression, high remission rates, and frequent relapse, with new risk factors identified to improve long-term prognosis and management.

Bariatric surgery, particularly sleeve gastrectomy, may improve survival and kidney transplant access in older adults with obesity and ESKD.

A curated recap of 8 impactful trial updates from the American Society of Nephrology Kidney Week 2025.

Stay updated with the latest healthcare breakthroughs, including FDA approvals and new Crohn's disease guidelines, in this week's essential news roundup.

Phase 3 trial shows MIL62 accelerates remission, reduces relapse risk, and improves kidney function compared with cyclosporine A in adults with primary MN.

Non-RASi antihypertensive use before pregnancy in women with IgAN increased the risk of severe HDP and preterm delivery.

Gill describes tegoprubart’s efficacy and safety for post-kidney transplant immunosuppression and reviews key phase 2 BESTOW trial data from ASN.

Dual BLyS/APRIL inhibition with telitacicept cut proteinuria and maintained kidney function in adults with IgA nephropathy.

ASN insights on felzartamab, a CD38-targeted therapy, show sustained immune modulation in IgA nephropathy, offering a novel treatment approach.

Dual BLyS/APRIL inhibition with telitacicept led to significant 24h-UPCR reductions, lower progression-risk thresholds, and stable eGFR compared with placebo.

ASN 2025 VALIANT data on pegcetacoplan show proteinuria reduction, including remission or reduction, in adolescents with C3G and IC-MPGN.